Quantum量子訊息有限公司
← 最新全球產業報告

Anticoagulant Market

研究執行與發布:Coherent Market Insights · 發布日期 2026-06-15 · 257 頁
由量子訊息有限公司(Quantum Information)在台灣代理銷售與提供授權諮詢。

2026 年市場規模
USD 46.1 Bn
2033 年預估規模
USD 83.5 Bn
年複合成長率 CAGR
8.9%

以上數字由 Coherent Market Insights 於本報告中提出,量子訊息原樣引用。

出版商 Coherent Market Insights產業別 Healthcare & Life Sciences出版日期 2026-06-15頁數 257報告編號 CMI5486

授權報價

Single User Price$4,500 USD
Enterprise License$10,000 USD
洽詢購買 申請 Sample
完整報告名稱與涵蓋範圍
Anticoagulant Market, By Drug Class (Novel Oral Anticoagulants (NOACs), Heparin and Low-molecular- weight Heparin (LMWH), and Vitamin K Antagonist), By Application (Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis (DVT), Pulmonary Embolism, and Other Applications), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Anticoagulants are a class of drugs that help prevent blood clots. They are commonly called blood thinners. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. Anticoagulants are commonly used to prevent and treat cardiovascular diseases (CVDs). Market Dynamics Growing prevalence of chronic disease, rise in demand for anticoagulants, increase in focus on the development of novel anticoagulants, and growing geriatric population across the globe are major factors expected to drive growth of the global anticoagulant market. For instance, in June 2022, Apotex Inc. announced the launch of APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots. Moreover, in June 2021, the Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets to treat children three months to 12 years old with venous thromboembolism. FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism. Key features of the study • This report provides in-depth analysis of the global anticoagulant market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year. • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market. • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players. • It profiles key players in the global anticoagulant market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies. • Key companies covered as a part of this study include Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics. • The global anticoagulant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts. • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulant market. Market Segmentation • By Drug Class (Revenue, USD Bn, 2021-2033) o Novel Oral Anticoagulants (NOACs) o Heparin and Low-molecular- weight Heparin (LMWH) o Vitamin K Antagonist • By Application (Revenue, USD Bn, 2021-2033) o Atrial Fibrillation/Myocardial Infarction (Heart Attack) o Deep Vein Thrombosis (DVT) o Pulmonary Embolism o Other Applications • By Region (Revenue, USD Bn, 2021-2033) o North America  U.S.  Canada o Latin America  Brazil  Mexico  Argentina  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Spain  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  South Africa  Central Africa  North Africa • Key Players o Pfizer Inc. o Sanofi SA o Reddy’s Laboratories o Aspen Holdings o Abbott Laboratories o Leo Pharma AS o Alexion Pharmaceuticals Inc. o Bayer AG o Johnson & Johnson o Bristol-Myers Squibb Company o Daiichi Sankyo Company o Boehringer Ingelheim Pharmaceuticals Inc.
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Drug Class  Market Snapshot, By Application  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Key Developments o Product Approval o Collaboration/Merge/Acquisition o Regulatory Landscape o PEST Analysis o Porter’s Five Forces Analysis o Epidemiology o Robust Pipeline Analysis 4. Global Anticoagulant Market, By Drug Class, 2021 – 2033, (USD Billion) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022– 2033  Segment Trends o Novel Oral Anticoagulants (NOACs)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Heparin and Low-molecular- weight Heparin (LMWH)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Vitamin K Antagonist  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) 5. Global Anticoagulant Market, By Application, 2021 – 2033, (USD Billion) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022– 2033  Segment Trends o Atrial Fibrillation/Myocardial Infarction (Heart Attack)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Deep Vein Thrombosis (DVT)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Pulmonary Embolism  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Other Applications  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) 6. Global Anticoagulant Market, By Region, 2021 – 2033, (USD Billion) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2022–2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion) o North Africa o Central Africa o South Africa 7. Competitive Landscape o Heat Map Analysis o Market Share Analysis o Company Profile  Pfizer Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Sanofi SA o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Dr. Reddy’s Laboratories o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Aspen Holdings o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Abbott Laboratories o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Leo Pharma AS o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Alexion Pharmaceuticals Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Bayer AG o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Johnson & Johnson o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Bristol-Myers Squibb Company o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Daiichi Sankyo Company o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Boehringer Ingelheim Pharmaceuticals Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies o Analyst Views 8. Section o References o Research Methodology o About Us

提及公司

Pfizer Inc.Sanofi SAReddy’s LaboratoriesAspen HoldingsAbbott LaboratoriesLeo Pharma ASAlexion Pharmaceuticals Inc.Bayer AGJohnson & JohnsonBristol-Myers Squibb CompanyDaiichi Sankyo CompanyBoehringer Ingelheim Pharmaceuticals Inc.

同分類最新報告(醫療與生命科學)

常見問題

這份報告可以先索取樣本嗎?

可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算?

報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付?如何付款?

一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們